|26th August 2020||Lindsay A Md Rosenwald||52,500||Open or private purchase||$18.00||$945,000.00|
|14th July 2020||Lindsay A Md Rosenwald||16,611||Grant/award etc.||$0.00|
|14th July 2020||Michael S Weiss||16,611||Grant/award etc.||$0.00|
|14th July 2020||Neil Herskowitz||16,611||Grant/award etc.||$0.00|
|22nd June 2020||Michael S Weiss||1,556,029||Grant/award etc.||$0.00|
|16th June 2020||Neil Herskowitz||10,000||Grant/award etc.||$0.00|
|5th June 2020||Barry M Salzman||24,390||Grant/award etc.||$0.00|
|5th June 2020||Neil Herskowitz||24,390||Grant/award etc.||$0.00|
|5th June 2020||Michael S Weiss||24,390||Grant/award etc.||$0.00|
|5th June 2020||Lindsay A Md Rosenwald||24,390||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company was founded on November 10, 2014 and is headquartered in New York.